"The US Food and Drug Administration (FDA) has approved soluble ferric pyrophosphate (Triferic, Rockwell Medical) to replace iron and maintain hemoglobin in adults with chronic kidney disease who are undergoing dialysis.
AlternativeTherapy in Severe Hyperkalemia: Since effective lowering of serum potassium with this product may take hours to days, treatment with this drug alone may be insufficient to rapidly correct severe hyperkalemia associated with states of rapid tissue breakdown (e.g., burns and renal failure) or hyperkalemia so marked as to constitute a medical emergency. Therefore, other definitive measures, including dialysis, should always be considered and may be imperative.
Hypokalemia: Serious potassium deficiency can occur from therapy with Kionex® (sodium polystyrene sulfonate) . The effect must be carefully controlled by frequent serum potassium determinations within each 24 hour period. Since intracellular potassium deficiency is not always reflected by serum potassium levels, the level at which treatment with Kionex® (sodium polystyrene sulfonate) should be discontinued must be determined individually for each patient. Important aids in making this determination are the patient's clinical condition and electro cardiogram. Early clinical signs of severe hypokalemia include a pattern of irritable confusion and delayed thought processes.
Electrocardiographically, severe hypokalemia is often associated with a lengthened Q-T interval, widening, flattening, or inversion of the T wave, and prominent U waves. Also, cardiac arrhythmias may occur, such as premature atrial, nodal, and ventricular contractions, and supraventricular and ventricular tachycardias. The toxic effects of digitalis are likely to be exaggerated. Marked hypokalemia can also be manifested by severe muscle weakness, at times extending into frank paralysis.
Electrolyte Disturbances: Like all cation-exchange resins, Kionex® Sodium Polystyrene Sulfonate is not totally selective (for potassium) in its actions, and small amounts of other cations such as calcium and magnesium can also be lost during treatment. Accordingly, patients receiving Kionex® (sodium polystyrene sulfonate) should be monitored for all applicable electrolyte disturbances.
Systemic Alkalosis:Systemic alkalosis has been reported after cation-exchange resins were administered orally in combination with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate. Magnesium hydroxide should not be administered with Kionex® (sodium polystyrene sulfonate) . One case of grand mal seizure has been reported in a patient with chronic hypocalcemia of renal failure who was given sodium polystyrene sulfonate with magnesium hydroxide as laxative. (See PRECAUTIONS: DRUG INTERACTIONS.)
Caution is advised when Kionex® (sodium polystyrene sulfonate) is administered to patients who cannot tolerate even a small increase in sodium loads (i.e., severe congestive heart failure, severe hypertension, or marked edema). In such instances compensatory restriction of sodium intake from other sources may be indicated.
In the event of clinically significant constipation, treatment with Kionex® (sodium polystyrene sulfonate) should be discontinued until normal bowel motion is resumed. Magnesium-containing laxatives or sorbitol should not be used (see PRECAUTIONS: DRUG INTERACTIONS).
Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies have not been performed.
Pregnancy Category C
Animal reproduction studies have not been conducted with Kionex® (Sodium Polystyrene Sulfonate, USP). It is also not known whether Kionex® (sodium polystyrene sulfonate) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Kionex® (sodium polystyrene sulfonate) should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Kionex® (sodium polystyrene sulfonate) is administered to a nursing woman.
Pediatric Use: The effectiveness of Kionex® (sodium polystyrene sulfonate) in pediatric patients has not been established. In neonates, Kionex® (sodium polystyrene sulfonate) should not be given by the oral route. In both children and neonates, particular care should be observed with rectal administration, as excessive dosage or inadequate dilution could result in impaction of the resin.
Last reviewed on RxList: 10/8/2007
Additional Kionex Information
Kionex - User Reviews
Kionex User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.